Prophylactic platelets in dengue: survey responses highlight lack of an evidence base
Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a re...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2012
|
| _version_ | 1797096670776786944 |
|---|---|
| author | Whitehorn, J Rodriguez Roche, R Guzman, M Martinez, E Gomez, W Nainggolan, L Laksono, I Mishra, A Lum, L Faiz, A Sall, A Dawurung, J Borges, A Leo, Y Blumberg, L Bausch, D Kroeger, A Horstick, O Thwaites, G Wertheim, H Larsson, M Hien, T Peeling, R Wills, B Simmons, C Farrar, J |
| author_facet | Whitehorn, J Rodriguez Roche, R Guzman, M Martinez, E Gomez, W Nainggolan, L Laksono, I Mishra, A Lum, L Faiz, A Sall, A Dawurung, J Borges, A Leo, Y Blumberg, L Bausch, D Kroeger, A Horstick, O Thwaites, G Wertheim, H Larsson, M Hien, T Peeling, R Wills, B Simmons, C Farrar, J |
| author_sort | Whitehorn, J |
| collection | OXFORD |
| description | Dengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue. |
| first_indexed | 2024-03-07T04:44:50Z |
| format | Journal article |
| id | oxford-uuid:d2e353d2-431c-4e2a-9187-ba64145610bb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:44:50Z |
| publishDate | 2012 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:d2e353d2-431c-4e2a-9187-ba64145610bb2022-03-27T08:07:31ZProphylactic platelets in dengue: survey responses highlight lack of an evidence baseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d2e353d2-431c-4e2a-9187-ba64145610bbEnglishSymplectic Elements at OxfordPublic Library of Science2012Whitehorn, JRodriguez Roche, RGuzman, MMartinez, EGomez, WNainggolan, LLaksono, IMishra, ALum, LFaiz, ASall, ADawurung, JBorges, ALeo, YBlumberg, LBausch, DKroeger, AHorstick, OThwaites, GWertheim, HLarsson, MHien, TPeeling, RWills, BSimmons, CFarrar, JDengue is the most important arboviral infection of humans. Thrombocytopenia is frequently observed in the course of infection and haemorrhage may occur in severe disease. The degree of thrombocytopenia correlates with the severity of infection, and may contribute to the risk of haemorrhage. As a result of this prophylactic platelet transfusions are sometimes advocated for the prevention of haemorrhage. There is currently no evidence to support this practice, and platelet transfusions are costly and sometimes harmful. We conducted a global survey to assess the different approaches to the use of platelets in dengue. Respondents were all physicians involved with the treatment of patients with dengue. Respondents were asked that their answers reflected what they would do if they were the treating physician. We received responses from 306 physicians from 20 different countries. The heterogeneity of the responses highlights the variation in clinical practice and lack of an evidence base in this area and underscores the importance of prospective clinical trials to address this key question in the clinical management of patients with dengue. |
| spellingShingle | Whitehorn, J Rodriguez Roche, R Guzman, M Martinez, E Gomez, W Nainggolan, L Laksono, I Mishra, A Lum, L Faiz, A Sall, A Dawurung, J Borges, A Leo, Y Blumberg, L Bausch, D Kroeger, A Horstick, O Thwaites, G Wertheim, H Larsson, M Hien, T Peeling, R Wills, B Simmons, C Farrar, J Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title_full | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title_fullStr | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title_full_unstemmed | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title_short | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base |
| title_sort | prophylactic platelets in dengue survey responses highlight lack of an evidence base |
| work_keys_str_mv | AT whitehornj prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT rodriguezrocher prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT guzmanm prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT martineze prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT gomezw prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT nainggolanl prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT laksonoi prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT mishraa prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT luml prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT faiza prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT salla prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT dawurungj prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT borgesa prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT leoy prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT blumbergl prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT bauschd prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT kroegera prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT horsticko prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT thwaitesg prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT wertheimh prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT larssonm prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT hient prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT peelingr prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT willsb prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT simmonsc prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase AT farrarj prophylacticplateletsindenguesurveyresponseshighlightlackofanevidencebase |